![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
Abstract
Gastric cancer is the second leading cause of cancer death worldwide. The local surgical treatment of gastric cancer varies geographically. However, there has been a confluence of opinion regarding the optimal therapy of gastric cancer toward multimodality therapy. In the East, many clinicians pursue adjuvant chemotherapy after a D2 resection. However, in the West, clinicians use either perioperative chemotherapy or postoperative chemoradiation. It remains unclear at this time whether either perioperative approach is the optimal approach.
Financial & competing interests disclosure
The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
No writing assistance was utilized in the production of this manuscript.